New Perspectives on the Treatment of Androgenetic Alopecia

New Medical Treatment for Androgenetic Alopecia

Dihydrotestosterone(DHT) has played the pathogenic role in androgenetic alopecia. Patients with genetic deficiency of 5 alpha-reductase type II enzyme, which converts testosterone to DHT, do not have androgenic alopecia. The conversion of testosterone to DHT at hair follicles leads to miniaturization. In scalp biopsy, the tissue DHT level is significantly increased in balded area than non-balde...

Androgenetic Alopecia

Androgenetic alopecia and current methods of treatment.

Androgenetic alopecia (AGA) is a common dermatological condition affecting both men and women. In the case of men, up to 30% over the age of 30 and more than 50% over the age of 50 are affected. AGA also affects women although clinical signs are usually milder and associated with diffuse thinning of the scalp hair. AGA invariably causes serious psychological problems especially in women. By far...

Topical Melatonin for Treatment of Androgenetic Alopecia

BACKGROUND In the search for alternative agents to oral finasteride and topical minoxidil for the treatment of androgenetic alopecia (AGA), melatonin, a potent antioxidant and growth modulator, was identified as a promising candidate based on in vitro and in vivo studies. MATERIALS AND METHODS One pharmacodynamic study on topical application of melatonin and four clinical pre-post studies wer...

Androgenetic alopecia: an evidence-based treatment update.

BACKGROUND Androgenetic alopecia (AGA) is one of the most common chronic problems seen by dermatologists worldwide. It is characterized by progressive hair loss, especially of scalp hair, and has distinctive patterns of loss in women versus men, but in both genders the central scalp is most severely affected. It often begins around puberty and is known to effect self-esteem and the individual's...